Ovarian Cancer | Specialty

EMA Recommends Approval of Olaparib/Bevacizumab for Frontline Maintenance in HRD+ Advanced Ovarian Cancer

September 21st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for olaparib as maintenance treatment in adult patients with advanced, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response after first-line platinum-based chemotherapy plus bevacizumab and whose disease has homologous recombination deficiency positivity defined by either a BRCA1/2 mutation and/or genomic instability.

Weekly Dose-Dense Chemotherapy Not Superior to Standard of Care in Epithelial Ovarian Cancer

September 21st 2020

Weekly dose-dense chemotherapy is not superior to standard 3 weekly chemotherapy for patients with epithelial ovarian cancer when it comes to progression-free survival and overall survival, though the regimen is safe and effective.

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian Cancer

September 18th 2020

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

September 9th 2020

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for ​evaluating lipophilic statins in epithelial ovarian cancer. 

Herzog and Moore Mull Over the Role of Maintenance PARP Inhibition in Ovarian Cancer

September 7th 2020

In our exclusive interview, Thomas Herzog, MD, and Kathleen Moore, MD, reviewed the topline results of the 4 positive PARP inhibitor trials in the frontline maintenance setting and provided perspective on the potential applications of these data to clinical practice.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

September 4th 2020

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Dr. O’Malley on the Safety Profile of Mirvetuximab in Ovarian Cancer

September 3rd 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

Coleman and Slomovitz Continue the Discussion on Maintenance PARP Inhibition in Ovarian Cancer

September 3rd 2020

In our exclusive interview, Robert L. Coleman, MD, FACOG, FACS and Brian M. Slomovitz, MD, discussed the benefits and limitations of PARP inhibition in all-comers with newly diagnosed advanced ovarian cancer and pivotal PARP inhibitor trials in the frontline setting.

Dr. Moore on Anticipated Impact of the MIRASOL Trial in Platinum-Resistant Ovarian Cancer

September 2nd 2020

Kathleen Moore, MD, discusses the anticipated impact of the phase 3 MIRASOL trial with mirvetuximab soravtansine in patients with platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer with a high folate receptor alpha expression.

Dr. Gilbert on Evaluating Mirvetuximab Soravtansine in Platinum-Agnostic Ovarian Cancer

August 26th 2020

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Surgery-Free Alternative Is Favorably Accepted Among Women at Risk of Ovarian Cancer

August 26th 2020

The majority of women at a high risk of developing ovarian cancer reported having a favorable attitude toward adopting a two-step risk-reducing early salpingectomy and delayed oophorectomy instead of a risk-reducing salpingo-oophorectomy.

Overcoming Racial Inequality in Epithelial Ovarian Cancer Research

August 26th 2020

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

Moore Highlights Hope for Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

August 25th 2020

In an interview with OncLive, Kathleen Moore, MD, discusses the MIRASOL trial and the hope for mirvetuximab soravtansine in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high FRα expression.

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

August 24th 2020

Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer

August 18th 2020

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Dr. Mirza on the Implications of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 17th 2020

Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Dr. Liu on Cediranib/Olaparib in Recurrent Ovarian Cancer

August 14th 2020

Joyce F. Liu, MD, MPH, discusses the results of cediranib in combination with olaparib in a phase 3 trial in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

August 13th 2020

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Markman and Monk Provide Perspective on the Utility of PARP Inhibitors in Ovarian Cancer

August 10th 2020

In our exclusive interview, Bradley J. Monk, MD, FACS, FACOG, and Maurie Markman, MD, discuss the rationale behind maintenance therapy, pivotal PARP inhibitor trials in the frontline setting, and the importance of shared-decision making.

Dr. Mirza on Final Data of the NSGO-AVANOVA2/ENGOT-OV24 Trial in Ovarian Cancer

August 3rd 2020

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.